サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793875

全身型若年性特発性関節炎の世界市場

Systemic Juvenile Idiopathic Arthritis

出版日
ページ情報
英文 365 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
全身型若年性特発性関節炎の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 365 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

全身型若年性特発性関節炎の世界市場は2030年までに22億米ドルに達する

2024年に18億米ドルと推定される全身型若年性特発性関節炎の世界市場は、2024～2030年の分析期間においてCAGR 3.7%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである薬剤治療は、CAGR 4.4%を記録し、分析期間終了時には15億米ドルに達すると予想されます。生物製剤治療セグメントの成長率は、分析期間中CAGR 2.1％と推定されます。

米国市場は4億8,370万米ドルと推定、中国はCAGR6.9％で成長予測

米国の全身型若年性特発性関節炎市場は、2024年に4億8,370万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.9%として、2030年までに4億4,570万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.9%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の全身型若年性特発性関節炎市場- 主要動向と促進要因のまとめ

全身型若年性特発性関節炎が小児の自己免疫治療で臨床的に優先される理由とは？

全身型若年性特発性関節炎（sJIA）は、全身性の炎症、持続的な発熱、発疹、関節腫脹を特徴とする若年性特発性関節炎のまれだが重篤な亜型です。他の関節炎とは異なり、sJIAはIL-1やIL-6などのサイトカインの調節異常がしばしば関与する自己炎症性疾患と考えられています。マクロファージ活性化症候群（MAS）のような合併症の可能性も含め、全身に影響を及ぼすため、sJIAは早期の診断と積極的な介入が必要です。この疾患は経過が予測できず、感染症や血液疾患と症状が重複するため、正確な診断が難しく、先進的なバイオマーカーや標的生物学的製剤への依存が高まっています。小児科医やリウマチ専門医の間で認識が高まるにつれ、長期的な転帰と生活の質を改善するための早期診断プロトコルと個別化治療戦略の開発に注目が集まっています。

治療イノベーションはsJIAの治療経路をどのように変えるのか？

主要な炎症性メディエーターを標的とする生物学的製剤は、治療の展望に革命をもたらしています。アナキンラ（IL-1遮断薬）やトシリズマブ（IL-6遮断薬）などのインターロイキン阻害薬は現在、中等度から重度のsJIAの標準治療薬となっており、迅速な症状コントロールとコルチコステロイド依存性の軽減を提供しています。JAK阻害剤を含む新しい治療法は、難治性症例の管理と再発予防のために臨床試験で検討されています。バイオマーカー主導のアプローチにより、より正確な治療標的やモニタリングが可能になりつつあります。遺伝子スクリーニング、サイトカインプロファイリング、疾患活動性スコアリングシステムは治療レジメンの調整に役立っています。さらに、皮下注射製剤や長時間作用型注射製剤の進歩により、小児患者のアドヒアランスが向上しています。これらの技術革新は、疾患の寛解と長期的な関節・臓器障害の予防に貢献しています。

sJIAの管理は、ヘルスケアの統合によってどこで改善されているのでしょうか？

sJIAの管理は、小児リウマチ専門医、免疫専門医、遺伝専門医を含む連携ケアパスを通して改善されています。北米、欧州、アジアの一部にsJIA専門のクリニックや紹介センターが設立され、集学的治療や治験治療へのアクセスが提供されています。遠隔医療プラットフォームは、特に遠隔地や十分なサービスを受けていない地域において、疾患のモニタリングや服薬アドヒアランスを向上させています。患者登録とリアルワールドエビデンス（RWE）研究は、長期的な薬剤の有効性と安全性を追跡するために利用され、治療ガイドラインや規制決定に情報を提供しています。政府の医療機関や小児科擁護団体も、早期介入プログラムや啓発キャンペーンに資金を提供しており、診断の遅れを減らすのに役立っています。このような協力的な取り組みにより、世界的にsJIA患者へのアクセスと治療の質の両方が向上しています。

全身型若年性特発性関節炎市場の成長はいくつかの要因によって牽引されている...

小児自己免疫疾患の罹患率の増加、サイトカイン標的生物製剤の進歩、診断プロトコルの改善などがその原動力です。IL-1阻害剤とIL-6阻害剤の承認は、効果的でステロイドを節約できる治療レジメンの新たな基準を確立しました。また、次世代生物製剤やJAK阻害剤などの経口低分子を研究する小児臨床試験も成長を支えています。小児リウマチ診療の拡大と希少疾患登録へのsJIAの登録により、患者の特定と治療へのアクセスが増加しています。ヘルスケア政策の強化、デジタルモニタリングツール、介護者教育プラットフォームは、長期的な疾患管理をさらに支援しています。

セグメント

治療タイプ（薬物治療、生物製剤治療、その他の治療タイプ）、投与ルート（経口ルート、注射ルート、その他の投与ルート）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • AbbVie
  • Alteogen Inc.
  • AstraZeneca
  • Bristol-Myers Squibb（BMS）
  • Cadila Healthcare Ltd.
  • Celltrion Healthcare
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Genentech（Roche）
  • Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Johnson & Johnson（Janssen）
  • LATAM Pharma
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.
  • UCB SA
  • Zydus Cadila**（Cadila Healthcare）

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38158

Global Systemic Juvenile Idiopathic Arthritis Market to Reach US$2.2 Billion by 2030

The global market for Systemic Juvenile Idiopathic Arthritis estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Biologics Treatment segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.7 Million While China is Forecast to Grow at 6.9% CAGR

The Systemic Juvenile Idiopathic Arthritis market in the U.S. is estimated at US$483.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$445.7 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Systemic Juvenile Idiopathic Arthritis Market - Key Trends & Drivers Summarized

Why Is Systemic Juvenile Idiopathic Arthritis a Clinical Priority in Pediatric Autoimmune Care?

Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare but severe subtype of juvenile idiopathic arthritis characterized by systemic inflammation, persistent fever, rash, and joint swelling. Unlike other forms of arthritis, sJIA is considered an autoinflammatory disease, often involving the dysregulation of cytokines such as IL-1 and IL-6. Due to its systemic impact-including potential complications like macrophage activation syndrome (MAS)-sJIA demands early diagnosis and aggressive intervention. The condition’s unpredictable course and overlapping symptoms with infectious or hematologic diseases make accurate diagnosis challenging, increasing the reliance on advanced biomarkers and targeted biologics. As awareness grows among pediatricians and rheumatologists, there is heightened focus on developing early diagnostic protocols and personalized treatment strategies to improve long-term outcomes and quality of life.

How Are Therapeutic Innovations Transforming sJIA Treatment Pathways?

Biologic therapies targeting key inflammatory mediators are revolutionizing the treatment landscape. Interleukin inhibitors such as anakinra (IL-1 blocker) and tocilizumab (IL-6 blocker) are now standard-of-care for moderate to severe sJIA, offering rapid symptom control and reduced corticosteroid dependence. Newer therapies including JAK inhibitors are being explored in clinical trials to manage refractory cases and prevent relapse. Biomarker-driven approaches are enabling more precise therapeutic targeting and monitoring. Genetic screening, cytokine profiling, and disease activity scoring systems are helping tailor treatment regimens. Additionally, advancements in subcutaneous and long-acting injectable formulations are improving adherence in pediatric patients. These innovations are contributing to disease remission and prevention of long-term joint and organ damage.

Where Is sJIA Management Improving Through Systemic Healthcare Integration?

sJIA management is being improved through coordinated care pathways involving pediatric rheumatologists, immunologists, and geneticists. Specialized sJIA clinics and referral centers are being established in North America, Europe, and parts of Asia to provide multidisciplinary care and access to investigational treatments. Telehealth platforms are enhancing disease monitoring and medication adherence, especially in remote or underserved regions. Patient registries and real-world evidence (RWE) studies are being used to track long-term drug effectiveness and safety, informing treatment guidelines and regulatory decisions. Government health agencies and pediatric advocacy groups are also funding early intervention programs and public awareness campaigns, helping reduce diagnostic delays. These collaborative efforts are enhancing both access to and the quality of care for sJIA patients globally.

The Growth in the Systemic Juvenile Idiopathic Arthritis Market Is Driven by Several Factors…

It is driven by increasing incidence of pediatric autoimmune diseases, advancements in cytokine-targeted biologics, and improved diagnostic protocols. The approval of IL-1 and IL-6 inhibitors has established new standards in effective, steroid-sparing treatment regimens. Growth is also supported by pediatric clinical trials investigating next-generation biologics and oral small molecules such as JAK inhibitors. Expansion of pediatric rheumatology services and inclusion of sJIA in rare disease registries are increasing patient identification and therapeutic access. Enhanced healthcare policies, digital monitoring tools, and caregiver education platforms are further supporting long-term disease management.

SCOPE OF STUDY:

The report analyzes the Systemic Juvenile Idiopathic Arthritis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Drug Treatment, Biologics Treatment, Other Treatment Types); Administration Route (Oral Route, Injectable Route, Other Routes of Administration); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie
  • Alteogen Inc.
  • AstraZeneca
  • Bristol-Myers Squibb (BMS)
  • Cadila Healthcare Ltd.
  • Celltrion Healthcare
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Genentech (Roche)
  • Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Johnson & Johnson (Janssen)
  • LATAM Pharma
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.
  • UCB SA
  • Zydus Cadila** (Cadila Healthcare)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Systemic Juvenile Idiopathic Arthritis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness and Early Diagnosis Rates of Pediatric Autoimmune Conditions Drive sJIA Treatment Demand
    • Rising Use of Biologics and Targeted Therapies Expands Treatment Options for Severe Cases
    • Advancements in Interleukin Inhibitor Research Propel Innovation in sJIA Drug Development
    • Improved Understanding of Disease Pathophysiology Enhances Precision in Treatment Selection
    • Expansion of Pediatric Rheumatology Clinics Increases Access to Specialized Care
    • Inclusion of sJIA Treatments in National Formularies Supports Prescription Growth
    • Rising Availability of Subcutaneous and At-Home Therapy Options Improves Patient Adherence
    • Ongoing Clinical Trials for Corticosteroid-Sparing Therapies Fuel Pipeline Interest
    • Growth in Companion Diagnostic Use Strengthens Market for Personalized Medicine in sJIA
    • Education and Advocacy Among Caregivers and Physicians Drive Early Intervention Trends
    • Monitoring of Long-Term Side Effects Spurs Interest in Safer, More Targeted Treatment Regimens
    • Use of Multidisciplinary Care Models Increases Treatment Consistency and Outcomes in Pediatric Patients
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Systemic Juvenile Idiopathic Arthritis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Drug Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION